Lantheus (NASDAQ:LNTH) Upgraded to “Strong-Buy” at BidaskClub

BidaskClub upgraded shares of Lantheus (NASDAQ:LNTH) from a buy rating to a strong-buy rating in a report released on Friday morning, BidAskClub reports.

A number of other analysts have also commented on LNTH. CJS Securities raised Lantheus from a market perform rating to an outperform rating in a research note on Friday, August 16th. ValuEngine lowered Lantheus from a buy rating to a hold rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research lowered Lantheus from a hold rating to a sell rating in a research note on Friday, August 2nd. One analyst has rated the stock with a sell rating, two have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $29.00.

LNTH opened at $26.38 on Friday. The company has a quick ratio of 2.01, a current ratio of 2.62 and a debt-to-equity ratio of 2.05. The firm has a market cap of $1.00 billion, a P/E ratio of 26.37, a PEG ratio of 2.15 and a beta of 1.50. Lantheus has a 52 week low of $12.59 and a 52 week high of $29.80. The business’s fifty day simple moving average is $22.86 and its 200 day simple moving average is $24.80.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, July 25th. The medical equipment provider reported $0.27 EPS for the quarter, meeting analysts’ consensus estimates of $0.27. The business had revenue of $85.70 million for the quarter, compared to analyst estimates of $88.72 million. Lantheus had a return on equity of 51.08% and a net margin of 11.20%. The business’s revenue for the quarter was up .1% compared to the same quarter last year. During the same quarter last year, the company earned $0.25 earnings per share. As a group, equities analysts expect that Lantheus will post 1 EPS for the current fiscal year.

In other news, Director Brian A. Markison sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $28.41, for a total value of $142,050.00. Following the transaction, the director now directly owns 32,467 shares in the company, valued at approximately $922,387.47. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Michael P. Duffy sold 7,500 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $23.74, for a total value of $178,050.00. Following the completion of the transaction, the senior vice president now owns 131,390 shares in the company, valued at $3,119,198.60. The disclosure for this sale can be found here. Over the last three months, insiders sold 97,965 shares of company stock worth $2,504,226. 2.60% of the stock is owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the company. Quantamental Technologies LLC purchased a new position in shares of Lantheus in the 2nd quarter worth about $56,000. Glen Harbor Capital Management LLC increased its holdings in Lantheus by 100.0% during the 2nd quarter. Glen Harbor Capital Management LLC now owns 2,336 shares of the medical equipment provider’s stock worth $66,000 after purchasing an additional 1,168 shares during the last quarter. Tyers Asset Management LLC increased its holdings in Lantheus by 100.0% during the 2nd quarter. Tyers Asset Management LLC now owns 3,212 shares of the medical equipment provider’s stock worth $91,000 after purchasing an additional 1,606 shares during the last quarter. Riverhead Capital Management LLC increased its holdings in Lantheus by 100.0% during the 2nd quarter. Riverhead Capital Management LLC now owns 3,600 shares of the medical equipment provider’s stock worth $102,000 after purchasing an additional 1,800 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new stake in Lantheus during the 2nd quarter worth approximately $103,000. Institutional investors own 95.72% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Read More: Certificate of Deposit (CD)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.